Vitamin K antagonists in patients with nonvalvular atrial fibrillation: Appropriateness and quality of treatment in an Italian cohort

Journal of Cardiovascular Medicine

Volumn 14, Issue 7, 2013, Pages 534-540

  De Sousa, Luis Pereira ^a   Burba, Ivana ^b   Ruperto, Cettina ^a   Lattuada, Luca ^b   Barbone, Fabio ^c   Di Chiara, Antonio ^a  

^a Agency for Health Services No 3 'Upper Friuli'   (Italy)

^b Agency for Health Services No 3 'Upper Friuli'   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Appropriateness; Atrial fibrillation; Clinical practice; Oral anticoagulation; Quality of treatment; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; PROTHROMBIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; ICD-9-CM; INTERNATIONAL NORMALIZED RATIO; ITALY; MAJOR CLINICAL STUDY; NONVALVULAR ATRIAL FIBRILLATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DRUG PRESCRIPTIONS; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HOSPITALS; HUMANS; ITALY; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT DISCHARGE; RISK ASSESSMENT; STROKE; TIME FACTORS; VITAMIN K;

EID: 84879209181     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32835dbd58     Document Type: Article

References (23)

1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86:516-521. (Pubitemid 32999861)
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864- 2870. (Pubitemid 32537350)
4. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
5. Mazzaglia G, Filippi A, Alacqua M, et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010; 103:968-975.
6. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in highrisk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2008; 40:235-240.
7. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029- 2037.
8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-239. (Pubitemid 23069000)
9. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008; 39:7-9.
10. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008; 39:227-230.
11. Ang SY, Peterson GM, Friesen WT, Vial JH. Review of antithrombotic drug usage in atrial fibrillation. J Clin Pharm Ther 1998; 23:97-106. (Pubitemid 28464376)
12. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke 2006; 37:1969-1974. (Pubitemid 44309888)
13. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11:423-434.
14. Di Chiara A, Di Lenarda A, Massa L, et al. Implementation of stroke prevention guidelines in patients with lonely atrial fibrillation; a Regional Outpatient Clinic Study. Proceedings of the 42th Italian National Cardiology Congress, ANMCO (National Association of Hospital Cardiologist) 2011; 12 (Suppl. 1 to N5).
15. Ogilvie IM, Welner SA, Cowell W, Lip GY. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol 2011; 108:151-161.
16. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Int Med 1994; 154:1449-1457.
17. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501. (Pubitemid 29482392)
18. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preferencebased antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29:1083-1091. (Pubitemid 28265459)
19. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239-245.
20. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
21. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
22. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
23. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32:2282-2289.